PMC6381921_01
Within 2 weeks after restarting erlotinib, severe pruritus developed again, followed by acneiform skin rush especially on her face.
cro-0012-0084-g01.jpg
PMC6381921_01_cro-0012-0084-g01.jpg
F1
However, within 2 weeks after restarting erlotinib, severe pruritus of grade 3 developed again, followed by acneiform skin rush especially on her face (Fig. 1).
Within 5 days after starting the first 3-day dose of aprepitant, the prompt improvement of the pruritus and skin rush was observed.
cro-0012-0084-g02.jpg
PMC6381921_01_cro-0012-0084-g02.jpg
F2
Then, the prompt improvement was observed within 5 days after starting the first dose of aprepitant, leading to a score of 2 for the pruritus on the VAS (Fig. 2).
Within 4 weeks after starting the first 3-day dose of aprepitant, the pruritus and skin rush again exacerbated.
cro-0012-0084-g03.jpg
PMC6381921_01_cro-0012-0084-g03.jpg
F3
However, the pruritus and skin rush gradually exacerbated thereafter, leading to scores of 4 and 8 for the pruritus on the VAS within 2 and 4 weeks, respectively (Fig. 3).
After adopting the bi-weekly schedule of the 3-day dose of aprepitant, the pruritus and skin rush remained well-controlled throughout the subsequent treatment with erlotinib.
cro-0012-0084-g04.jpg
PMC6381921_01_cro-0012-0084-g04.jpg
F4
As the results, throughout the subsequent treatment with erlotinib, the pruritus and skin rush remained well-controlled within the scores of 2 and 4 for the pruritus on the VAS (Fig. 4).